Intra-Cellular price target raised to $89 from $81 at JPMorgan

JPMorgan raised the firm’s price target on Intra-Cellular (ITCI) to $89 from $81 and keeps an Overweight rating on the shares. The firm increased Caplyta estimates on the back of Intra-Cellular’s Q3 results and updated guidance. For the first time, Intra-Cellular provided long-term guidance and expects to see Caplyta sales of at least $5B within 10 years, the analyst tells investors in a research note.